Chongqing Mingdao Test Biotechnology Co., Ltd. (hereinafter referred to as Ming Daojie test) was established in 2020 and is headquartered in Chongqing High -tech Zone. Mingdaojiejie specializes in the research and development, manufacturing, marketing and services of diagnostic reagents and supporting instruments. The products are used in clinical examination, grass -roots medical care, epidemic monitoring, on -site law enforcement, and family personal health management. Mingdaojie is particularly important to develop products in the field of infectious disease diagnosis. Using the advanced immunohistocytics technology it has, it has developed a new type of coronary virus (SARS-COV-2), Hepatitis B Virus, and C Hepatitis C Virus (Hepatitis C Virus) has excellent in vitro diagnostic diagnostic, which has excellent product performance and is comparable to that of the same type of products in international mainstream brands.

The head office Artron Bioresearch Inc. is one of the largest companies in the Canadian external diagnostic industry. The company has a scientific research team with strong technical force and experienced development experience composed of multiple post -doctorals and doctors. The research and development technology of cloning antibodies, restructuring antigens and in vitro diagnostic test agents has provided reliable guarantees for the smooth implementation of biomedical research and in vitro diagnostic product development. Many domestic institutions and scientific research institutions jointly undertake a number of high -tech projects in the country. With the rapid development of the international and domestic external diagnostic industries, China Ogaca Biotechnology (Chongqing) Co., Ltd., as one of the important strategic layouts of the headquarters in Asia, is committed to combining foreign advanced R & D technology with Chinese medical practice with Chinese medical practice. , Continuously innovate and promote the rapid development of the in vitro diagnosis. The company will adhere to the vision of 'becoming a biotechnology company with international competitiveness' as the company's vision, driven by innovation, relying on talent, and technology as the core to contribute to improving people's health medical level!

Relying on the scientific research resources of the Shanghai Institute of Pharmaceuticals of the Chinese Academy of Sciences, the team of scientists and teams leads the New Territories, and it is invested by Bo Jiyuan (Shanghai) Biomedical Co., Ltd. The company is based on the close cooperation of the scientist team of Shanghai Pharmaceutical Research Institute for many years, with the goal of "Best in Class" and "First In Class", and is committed to the research and development of small molecular innovation drugs that really originate from Chinese original small molecular innovation drugs. The company will continue to improve the new drug research and development professional team and innovative product pipelines, and determines to build a first -class innovative pharmaceutical company.

The company's advantage is to focus on the analysis and interpretation of the results of the second -generation gene sequencing technology (NGS), especially in the field of all genome (WGS), outer appende (WES) and targeted genes (GENE PANEL) in the field of genetic diseases and rare diseases. In terms of the interpretation of biological informatics and the labeling of the test results, it has significant technical advantages (high accuracy, short analysis cycle). Enterprise -oriented and service scientific research, based on core technical advantages, has established a complete set of detection and analysis technology systems, developed a gene sequencing interpretation service, genetic disease gene diagnosis, pathogeniacerine group (MNGS) test, and new coronary virus testing, etc. Products in multiple directions can provide precision medical services for domestic cancer patients, genetic diseases, and healthy people, and provide clinical medical workers and scientific researchers with comprehensive and diversified comprehensive and diversified comprehensive and diversified aspects of high -throughput sequencing (NGS). A complete solution of the whole genome detection.

Started and founded by more than a dozen experts in the medical and education fields from the Army Military Medical University, Southwest University, and Chongqing Institute of Posts and Telecommunications, Focus on smart medical care, smart management, smart services, smart science and education, focus on the research and development of technologies such as smart medical core technology, health big data set, intelligent evaluation system, smart medical information platform, medical education ecological platform, and healthy development and health. Information consulting services such as psychology, occupation.

The predecessor of Chongqing Jidzhe Biotechnology Company is Sichuan Jiduzhe Medical Devices Company. Medical IVD Research Institute platform, heavy medical advantages and other colleges and universities, the results of Beijing Hengyi New Science and Technology Research Institute have accumulated strong R & D team guarantees, Square One's service help, which will recently complete some technical projects (blood condensation products, multi -functional multi -functional While the production and market transformation of more than 20 instruments and reagents registered by POCT products, new crown epidemic products), it will also accelerate the expansion of product upgrades and extension and new project research and development; the purpose of the company is to fully meet the inspection and inspection equipment of hospitals at all levels The demand for reagent consumables (IVD) can comprehensively improve the technical level of primary medical care (village medical stations, community medical stations) testing, diagnosis and treatment and other technical levels by cutting into the capital market.

The company is mainly engaged in the research and development, production, sales and technical services of biological reagents. The main businesses include reorganized protein, antibodies, genes and other products, as well as CRO services such as the development of restructuring protein, antibody, and biological analysis detection. The company is in the start -up stage and plans to financing RMB 10 million, which is mainly used for product development and supplementary project startup funds. The company's development strategy and operating goals are "based on the west, serving the country, and going to the world", and are committed to becoming the country's leading protein and antibody biological reagent products supply and service providers.

Chongqing Qimai Medical Technology Co., Ltd. is a professional medical device CRO company. It is established by the Yifang Enterprise Incubator (Chongqing) Co., Ltd. and Beijing Mai Ruisheng Pharmaceutical Technology Co., Ltd. The company integrates two directors of the company, focusing on the registration of medical devices and in vitro diagnostic reagents before listing, clinical assessment and clinical trials. It aims to help Chongqing Medical University International In vitro Diagnosis Research Institute, Square One Innovation Center, and Chongqing medical device enterprises in the last step before the listing of medical device.

Focus on the research and development, production, sales and services of internal diagnostic reagents and supporting instruments. The company's main team has more than 15 years of experience and rich channel resources in the body's diagnosis industry, and has close cooperation with well -known universities and IVD companies at home and abroad. Yibang Biology will be based on the team of Chongqing Medical University International IVD Research Institute and the Inspection College to establish a platform for development and development platforms such as molecular diagnosis, thrombosis and hemostasis, autoimmune, and rapid diagnosis. The first -class diagnostic kit of property rights serves human health. The market covers the country and even the world. The company establishes the research and development and manufacturing center of experimental instruments in Shenzhen, making full use of Shenzhen's unique location advantages. The complete industrial chain cluster and developed electromechanical integration manufacturing capabilities, high -efficiency manufacturing experimental instruments required for supporting reagents.

The company consists of a scientist team with a strong basis of scientific research at the same time in molecular detection and treatment. The main direction is to develop a technical platform for the exogenous MRNA delivery system, and multiple MRNA treatment methods are being developed. It is the first company to treat MRNA treatment in the body through the EV of EVs transformed through biological engineering. The first MRNA treatment company with GMP cleaning workshop.

The company specializes in the development and industrialization of medical equipment such as external testing equipment, clinical surgical equipment, life support equipment, rehabilitation physiotherapy equipment, medical beauty equipment, microfluidic chips, and microfluidic chips. With many years of research and development experience in the medical industry, team members have reserved a lot of advanced medical technology. In order to effectively transform more exclusive patented technologies with independent intellectual property rights, the establishment of Xingxing Biotechnology Co., Ltd. at Chongqing at the end of 2020. At present, existing product projects enter the registered testing stage. In the next three years, there will be no less than 10 medical products. Registration, production and sales.

Focus on the entire aging process and provide old residues with the leasing, sales and service of aging products such as chatting, helping music, assistance, urgency, medical assistance, help, bathing, meal aid, and aid. The company's main team has more than 5 years of experience and rich channel resources in the rehabilitation auxiliary device industry, and has close cooperative relationships with well -known universities such as Harbin Institute of Technology.

Chongqing Beituo Qiming Biomedical Research Institute Co., Ltd., founded in 2022, is located in Chongqing. It is a company that mainly engaged in research and experimental development.

Chongqing Yuyue Listening Medical Engineering Technology Co., Ltd. is the only high-tech company in the world that has built the whole industry chain of hearing health and integrated "production, study, research and medicine". The company is committed to leveraging the 100-billion-level hearing health industry, and leading domestic related industries to settle in Chongqing. The company has achieved the goal of domestic substitution and curve overtaking in the whole industry chain, and has been selected as the key database of the national industry-university-research integration platform of the Municipal Development and Reform Commission.

The company's core products: 1. "Cloud listening" belongs to business model innovation, professional and technical service force at the lower level, and can be quickly copied, quickly mined and transformed effective demand; 2. "Xinsheng Xiyu" precision rehabilitation software has helped congenital deaf and mute adolescent cochlear implant implanters to hear clearly and speak fluently high-quality rehabilitation goals, successfully solved world-class problems, and is stepping up promotion and building an ecological chain; 3. The cost-effective hearing diagnosis products, hearing aids and cochlear implants developed by shareholders have achieved annual sales of 100 million yuan; 4. Integrate the top scientific research teams at home and abroad and make every effort to develop the fully implanted cochlear implant/hearing aid system, which provides the greatest guarantee for surpassing strong foreign brands.

Less than 3 months after the establishment of the company, the sales revenue of technical services and products has achieved rapid growth, 420,000 yuan in May, 2.2 million yuan since June, and is expected to achieve sales revenue of more than 20 million yuan this year. The company pays attention to innovation and has incubated 6 undergraduate team entrepreneurial projects in our university, including cloud listening, new sound and joy, and tinnitus rehabilitation. At the same time, the "Listening Caravan" public welfare project is being promoted.

Headquartered in the Jinyun Campus of Chongqing Medical University, Brilliance Health is the first supplier and operator in China to apply virtual reality VR technology to "patient health education" based on the Square one China Innovation Center platform. We are committed to using the most advanced science and technology to build a cognitive bridge between doctors and patients, build an easy-to-understand, vivid and interesting medical knowledge platform that benefits the people and the country, and strive to establish a system to guide patients for reasonable treatment with the help of doctors, so that the 130 million diabetics and other acute and chronic disease patients in China can achieve a healthy and long life! We have set up branches in Chongqing, Beijing, Shanghai, Guangzhou, Hangzhou, Shenzhen, Chengdu, Nanning and other municipalities and provincial capitals, and strive to build a morning of Chinese health and disease prevention and control, so that every patient knows their disease early, acts early, and benefits early is our ultimate goal.

The company respects contracts and keeps promises, in line with the principle of quality first and integrity first, strengthens cooperation, optimizes and improves product quality in cooperation, and strives to create a new situation of "win-win cooperation". We promise that the company will continue to be patient-centered, relying on science and technology, gradually update the existing equipment to improve product quality, and continuously introduce senior management and technical talents to improve the management ability and technical level of the enterprise, so that the enterprise can better serve doctors and patients.